Biotech News
Polyrizon Begins GMP Manufacturing for PL-14 Allergy Blocker Ahead of 2025 Clinical Trial
Polyrizon, a biotech company focused on innovative intranasal hydrogels, has announced the commencement of Good Manufacturing Practice (GMP) manufacturing preparations for its PL-14 allergy blocker. This milestone is a critical step in readiness for the company’s planned 2025 clinical trial.
24 January 2025